BXCL 501

Drug Profile

BXCL 501

Alternative Names: BXCL501

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inveni
  • Developer BioXcel Therapeutics
  • Class Anxiolytics; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Agitation

Most Recent Events

  • 03 Nov 2017 Phase-I clinical trials in Agitation in USA (Sublingual) prior to 03/11/2017 (BioXcel pipeline, November 2017)
  • 30 Apr 2017 BioXcel Therapeutics in-licenses BXCL 501 from Inveni (Inveni website, April 2017)
  • 17 Apr 2017 Preclinical trials in Agitation in USA (Sublingual) (BioXcel Corporation pipeline, April 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top